Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia – preliminary study

Israel Journal of Psychiatry

Volumn 52, Issue 1, 2015, Pages 12-16

  Amiaz, Revital ^a,b   Kent, Ilan ^b   Rubinstein, Katya ^b   Sela, Ben Ami ^b   Javitt, Daniel ^c   Weiser, Mark ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; SARCOSINE;

ADULT; COMBINATION DRUG THERAPY; FEMALE; HUMAN; MALE; MIDDLE AGED; PILOT STUDY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SARCOSINE; SCHIZOPHRENIA;

EID: 84939430505     PISSN: None     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308
2. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998;44:1081-1089
3. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36
4. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophr Res 2005;72:225-234
5. Supplisson S, Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 1997;17:4580-4590
6. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55:452-456
7. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005;62:1196-1204
8. Gobert A, Rivet JM, Billiras R, Parsons F, Millan MJ. Simultaneous quantification of d- vs. l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: Differential modulation by N-methyl-d-aspartate (NMDA) and other pharmacological agents. J Neurosci Methods 2011;202:143-157
9. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS Psychometric and Standardization Study Am J Psychiatry 2008;165:221-228
10. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457(7231):910-914
11. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 2010;47:282
12. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders (SCID). New York: Biometrics Research, New York State Psychiatric Institute, 1997
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
14. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. Initial validation. J Nerv Ment Dis 1994;182:631-638
15. Blair JR, Spreen O. Predicting premorbid IQ: A revision of the national adult reading test. Clinical Neuropsychologist 1989;3:129-136
16. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68:283-297
17. Army Individual Test Battery: Manual of Directions and Scoring. Office AGs, editor. Washington, D.C.: U.S. War Department, 1944
18. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L The Continuous Performance Test, identical pairs version (CPT-IP): I New findings about sustained attention in normal families. Psychiatry Res 1988;26:223-238
19. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997;54:159-165
20. Wechsler D. Wechsler Memory Scale. 3 ed: San Antonio: The Psychological Corporation, 1997
21. Brandt J, Benedict RHB. The Hopkins Verbal Learning Test-Revised Odessa, FL, USA: Psychological Assessment Resources, Inc., 2001
22. Benedict RHB. Brief Visuospatial Memory Test - Revised. Odessa, FL, USA: Psychological Assessment Resources, Inc., 1997
23. White T, Stern RA. Neuropsychological Assessment Battery: Psychological Assessment Resources, Inc., 2003
24. Vakil E, Blachstein H. Rey Auditory-Verbal Learning Test: Structure analysis. J Clin Psychol 1993;49:883-890
25. Guy W. CGI: Clinical Global Impressions. Bonato WGaRR, editor: National Institute of Mental Health, 1976
26. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl 1970;212:11-19
27. Fann WE, Stafford JR, Malone RL, Frost JD, Richman BW. Clinical research techniques in tardive dyskinesia. Am J Psychiatry 1977;134:759-762
28. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-251
29. Crabb JW, Atherton D, Smith A, Kutny R. A collaborative amino acid analysis study from the Association of Biomolecular Resource Facilities Academic Press, 1990
30. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G, Jung K. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2011;185:706-711
31. Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE. Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol Psychiatry 2008 1;63:9-12
32. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia Int J Neuropsychopharmacol 2010;13:451-460
33. Hashimoto K. Glycine transporter-1: A new potential therapeutic target for schizophrenia. Curr Pharm Des 2011;17:112-120